IGI Logo

Shilpa Biologicals Private Limited (SBPL) subsidiary of Shilpa Medicare Limited, has entered into a 3 year DefInitive Agreement with Dr. Reddy's Laboratories Limited (DRL) for production-supply of the Sputnik V vaccine from its integrated biologics R&D cum manufacturing center at Dharwad, Karnataka.

The targeted production of the dual vector Sputnik V for the fIrst 12 months is 50 million doses (50 million of Component 1 and 50 million of Component 2), from the date of start of commercial production.

DRL has partnered with HVIRDIF for clinical development of the vaccine and has distribution rights in geographies including India. DRL will facilitate the transfer of the sputnik technology to SBPL. Under the agreement, SBPL will be responsible for manufacture of the vaccine, while DRL is responsible for distribution/marketing of the vaccine in its marketing territories.

The companies are also exploring the option to manufacture Sputnik Light, a single dose version of the vaccine in the near future.

This is very positive news for the Shilpa Medicare Limited.

Above views are of the author and not of the website kindly read disclaimer